Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

Summary

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Timeline

Start

2023-03-16

Primary completion

2029-12

Completion

2029-12

Drugs

Indications